Literature DB >> 11567695

Sponsorship, authorship, and accountability.

F Davidoff, C D DeAngelis, J M Drazen, J Hoey, L Højgaard, R Horton, S Kotzin, M G Nicholls, M Nylenna, A J Overbeke, H C Sox, M B Van Der Weyden, M S Wilkes.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Year:  2001        PMID： 11567695     DOI： 10.1016/s0140-6736(01)06035-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

Review 1.  Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

Authors:  Jeanne Lenzer
Journal:  BMJ       Date:  2002-03-23

2.  Disclosure of financial competing interests in randomised controlled trials: cross sectional review.

Authors:  Cary P Gross; Anu R Gupta; Harlan M Krumholz
Journal:  BMJ       Date:  2003-03-08

3.  Medical journals and pharmaceutical companies: uneasy bedfellows.

Authors:  Richard Smith
Journal:  BMJ       Date:  2003-05-31

Review 4.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

Review 5.  Conflict of interest as seen from a researcher's perspective.

Authors:  Arrigo Schieppati; Norberto Perico; Giuseppe Remuzzi
Journal:  Sci Eng Ethics       Date:  2002-07       Impact factor: 3.525

6.  Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.

Authors:  F Alfonso; A Timmis; F J Pinto; G Ambrosio; H Ector; P Kulakowski; P Vardas
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

7.  The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).

Authors:  O Bruyere; J A Kanis; M-E Ibar-Abadie; N Alsayed; M L Brandi; N Burlet; D L Cahall; A Chines; J-P Devogelaer; W Dere; N Goel; N Hughes; J-M Kaufman; S Korte; B H Mitlak; D Niese; R Rizzoli; L C Rovati; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-03-18       Impact factor: 4.507

Review 8.  Risk:benefit assessment of old medicines.

Authors:  Silvio Garattini; Vittorio Bertelé
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

9.  Good research conduct.

Authors:  J Grigg
Journal:  Arch Dis Child       Date:  2005-03       Impact factor: 3.791

10.  Patients' health or company profits? The commercialisation of academic research.

Authors:  Nancy F Olivieri
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.